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Abstract. – OBJECTIVE: Abnormal expres-
sion and activation of tropomyosin-related ki-
nase receptor B (TrkB) are observed in many 
pathological conditions, including many types 
of cancer. We try to explore the relationship be-
tween ovarian cancer and Brain-derived neuro-
trophic factor (BDNF), a ligand of TrkB.
MATERIALS AND METHODS: Human ovarian 
cancer cell line SKOV-3 was used in this study. 
qPCR, immunohistochemistry, and immunoblot 
were used to assay BDNF and TrkB expression 
level. Scratch assay was used to test the cell 
motility, and transwell assay was used to test 
the cell migration ability.
RESULTS: We found that BDNF promotes the 
proliferation and invasion of human ovarian can-
cer SKOV-3 cells depend on the activation of 
TrkB. To illuminate the downstream pathway of 
BDNF/TrkB, we silenced AKT1 and PLCγ1 by siR-
NA. The functional assay showed that activated 
PLCγ1 signaling pathway is necessary for the 
proliferation and invasion of cancer cells other 
than the AKT pathway. Further study showed that 
PLCγ1 could inhibit the apoptosis of cancer cells. 
CONCLUSIONS: BDNF triggers TrkB/PLCγ1 
signaling pathway to promote proliferation and 
invasion of ovarian cancer cells through inhibi-
tion of apoptosis.
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Introduction
Ovarian cancer is the third most common type of 
cancer and the fourth leading cause of cancer-relat-
ed death worldwide1,2. But the mechanism by which 
cancer develops still remains poorly understood. It 
is well known that growth factors and hormones are 
very important during the development of the ovary 
and other organs. Overexpression of growth factors 
and hormones, and abnormal expression or activa-
tion of their receptors may regulate the progression 
of many types of cancer including ovarian cancer3,4. 
Brain-derived neurotrophic factor (BDNF) is a 
very important nerve growth factor and its bind-
ing and subsequent activation of its receptor, Tro-
pomyosin-related kinase B (TrkB) plays a critical 
role in the development of nervous system5. More 
and more researches show that BDNF is a multi-
functional growth factor that exerts various effects 
on some non-neuronal cells and plays a role in the 
progression of pathological diseases6. Recently, the 
function of BDNF and TrkB is uncovered in many 
types of cancer such as breast cancer7. 
TrkB is a tyrosine kinase receptor which binds 
BDNF and is regarded as a potential target in several 
cancers. TrkB activates a couple of intracellular sig-
naling pathways to regulate cell proliferation, differ-
entiation, invasiveness, and angiogenesis8-10. 
We showed activation of BDNF/TrkB signaling 
pathway could promote cell proliferation and inva-
sion of ovarian cancer cells in vitro. We demon-
strated that expression of TrkB increased in the 
ovarian cancer tissues by immunohistochemistry. 
BDNF promotes the activation of TrkB in ovari-
an cancer cell line SKOV-3 as revealed by Western 
blot. Further results suggested that silence of TrkB 
resulted in a significant inhibition of cell prolifera-
tion and invasion induced by BDNF. By inhibition 
of downstream gene AKT1 and PLCγ1, we found 
that only silence of PLCγ1 blocked the effect of 
BDNF/TrkB. We finally showed that inhibition of 
TrkB or PLCγ1 promotes apoptosis of SKOV-3.
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Human ovarian cancer cell line SKOV-3 
(ATCC® HTB-77TM) was purchased from Amer-
ican Type Culture Collection (ATCC, Manas-
sas, VA, USA) and cultured in DMEM with 10% 
fetal bovine serum (Invitrogen, Carlsbad, CA, 
USA) supplemented with penicillin-streptomycin 
(1:100; Invitrogen, Carlsbad, CA, USA). All the 
cells were cultured in a humidified atmosphere of 
5% CO2 at 37°C.
For BDNF treatment, cells were seeded and 
treated with recombinant human BDNF (Bior-
byt Ltd, Cambridge, UK; Orb80270, 10 mg, Lot#: 
C9154) in FBS free medium at a dose of 0, 50, 
100 ng/ml, respectively. PBS was added as con-
trol. 48 h after treatment, cells were analyzed as 
indicated.
Western Blotting
30 μg proteins were denatured at 95°C for 5 min 
and loaded into each lane of 4%-12% polyacryl-
amide gels and then transferred onto nitrocellulose 
membranes (Bio-Rad, Hercules, CA, USA) at 100 
V for 60 min. The membrane was blocked with 
5% non-fat dry milk in Tris-Buffered Saline and 
Tween (TBST) for 1 h at RT with shaking. Then, 
we incubated it with anti-phosphor-TrkB (pTrkB, 
1:1000), anti-total-TrkB (TrkB, 1:1000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), anti-phos-
phor-AKT (pAKT1, 1:1000) or anti-total-AKT 
(AKT1, 1:1000) antibodies (Proteintech, Rose-
mont, IL, USA) for 16 h at 4°C. Then, we washed it 
3 times for 10 min with TBST, we incubated it with 
secondary antibodies conjugated with horseradish 
peroxidase (HRP) (1:10000, Proteintech, Rose-
mont, IL, USA) for 1 h. Detection was performed 
using the ECL kit (Pierce, Rockford, IL, USA). 
The β-actin signal was used as a loading control.
Immunohistochemistry
The samples were fixed in 4% paraformalde-
hyde (4% PFA) for 16 h and then embedded in 
paraffin. Immunohistochemical study of BDNF 
and TrkB protein expression was performed as 
following protocol. 5 μm sections were dewaxed 
in xylene twice for 10 min and rehydrated se-
quentially in (100% ethanol twice for 1 min, 95% 
ethanol twice for 1 min, 75% ethanol twice for 1 
min and ddH2O 1 min) and antigen retrieval was 
performed by heating the sections at 98°C with 10 
mM sodium citrate buffer pH6.0 for 15 min. Next, 
we added 3% H2O2 for 15 min to block endog-
enous peroxidase activity and followed by 10% 
goat serum blocking for 1 h at room temperature. 
Primary antibody (anti-TrkB 1:80, anti-BDNF 
1:60; Abcam, Cambridge, MA, USA) was added 
and incubated at 4°C overnight. The expression 
was detected by DAB (Zhongshan Jinqiao Bei-
jing). Sections were counterstained with hema-
toxylin and mounted. 
siRNA Transfection
To knockdown TrkB, AKT1 and PLCγ1, 
scramble control, siTrkB, siAKT1 and siPLCγ1 
siRNA were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Transfection of 
10 μM siRNA in RNAi Max lipid reagent (Invi-
trogen, Carlsbad, CA, USA) was performed in 
SKOV-3 cells according to the manufacturer’s 
instruction. 48 h after transfection cells were har-
vested for further study.
Cell Proliferation Assay
Cell Proliferation was determined by direct 
cell count. Cells were seeded in 24-well plates at 
low density (1x104) and allowed to attach over-
night. Then cells were treated with indicated re-
agents and then cultured for 5 days. After 5 days’ 
culture, cells were detached by trypsin/EDTA 
and counted in a hemocytometer.
Scratch Assay
In vitro scratch assay was used to assess cell 
motility. Cells were allowed to grow to conflu-
ence. Then a scratch was made in the cell layer 
with a sterile micropipette tip. The cell layer was 
washed twice with culture media and incubated 
for 24 h. The size of the scratch was measured at 
4 random sites.
Cell Migration and Invasion Assay
Cell migration assays were performed us-
ing modified Boyden chambers with 8 μm-pore 
polycarbonate membrane (Corning, Corning, NY, 
USA). Cells (5 x105 in 100 μl) in serum-free medi-
um were seeded in the upper compartment coated 
with 0.1% gelatin of the chamber or Matrigel (1:10 
dilution in medium) for invasion assay. BDNF in 
700 μl normal medium was added in lower wells 
as specified. Cells were allowed to migrate for 48 
h at 37°C in 5% CO2. Cells on the lower side of the 
membrane were fixed with 4% PFA, stained with 
1% crystal violet and counted under bright field 
under high power field (100x). For each triplicate, 
the number of cells in ten random fields was de-
termined, averaged counts were recorded.
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TUNEL Assay
TUNEL assay was performed using the TUNEL 
kit (Roche Diagnostics, Mannheim, Germany) ac-
cording to the manufacturer’s instructions. Brief-
ly, cells were fixed with 4% paraformaldehyde in 
PBS, permeated with 0.1% Triton X-100 in PBS 
and incubated with 50 μl TUNEL reaction mixture 
for 1 h at 37°C. The reaction was terminated by 
washing with 1 x PBS. Cells were counted in 5 ran-
domly-chosen different fields under a microscope, 
total 500 cells were counted, and the percentage of 
apoptotic cells was quantified.
Statistical Analysis
SPSS Statistical Package version 16 (SPSS 
Inc., Chicago, IL, USA) was used for statistical 
analysis and expressed as means SE. Independent 
two group’s analysis were made using the Stu-
dent’s t-test. p<0.05 was considered statistically 
significant.
Results
Highly Expression of BDNF and TrkB in 
Ovarian Cancer with Poor Prognosis
To study the expression and localization of 
BDNF and TrkB in ovarian cancer tissue, we 
performed immunohistochemistry, the result 
showed BDNF and TrkB localized at the cyto-
plasm and cell membrane of epithelial cells (Fig-
ure 1). Among the different diagnostic groups, 
the normal ovary tissue was negative for BDNF 
and TrkB and all the invasive cancers and the 
metastatic foci were positive. Protein expression 
of BNDF and TrkB were significantly higher in 
invasive cancer and metastatic foci when com-
pared with normal tissues. So BDNF and TrkB 
may play a role in the progression of ovarian car-
cinogenesis.
BDNF Promotes Proliferation 
and Migration and Invasion 
of Ovarian Cancer Cells
To assess the function of BDNF in the pro-
liferation of ovarian cancer, we treated SKOV-3 
cells with recombinant human BDNF, the results 
showed that BDNF could promote the prolifera-
tion of cancer cells (Figure 2A). We then studied 
the role of BDNF in controlling the migration and 
invasion of ovarian cancer cells. Using scratch 
wound healing assay, we showed that treatment 
of BDNF resulted in a significant upregulation of 
the migration capacity of SKOV-3 cells (Figure 
2B). Consistent with the scratch assay, transwell 
assay also showed a significant increase of cells 
migrated to the lower side of the membrane (Fig-
ure 2C). To assess the function of BDNF in the 
invasion ability of ovarian cancer, invasion of the 
Matrigel-coated transwell assay was performed. 
The result showed that BDNF promoted invasion 
of SKOV-3 cells significantly (Figure 2D). These 
results demonstrated that BDNF could promote 
proliferation and invasion capacity of ovarian 
cancer cells.
Figure 1. Highly expression of BDNF 
and TrkB in ovarian cancer with poor 
prognosis. Immunohistochemistry showed 
expression of BDNF and TrkB were ab-
sent in epithelium of normal ovary tissue 
but highly present in ovarian carcinomas. 
Representative pictures were shown.
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BDNF Upregulates Expression 
and Phosphorylation of TrkB and 
Enhances Cell Proliferation 
and Migration and Invasion
To gain further insight into the mechanism 
by which BDNF promotes the development of 
ovarian cancer, expression and phosphorylation 
of TrkB under treatment of BDNF were detected. 
Western blot of TrkB and phosphor-TrkB showed 
treatment of BDNF increased the expression and 
phosphorylation of TrkB significantly in SKOV-3 
cells (Figure 3A). Then, we silenced the expres-
sion of TrkB by siRNA, and proliferation, mi-
gration and invasion assay were performed. The 
results showed without TrkB expression, BDNF 
couldn’t enhance cell proliferation and migration 
and invasion (Figure 3B, 3C and 3D).
TrkB/PI3K Signaling Pathway Is 
Not Necessary to Promote Proliferation 
and Migration of Ovarian Cancer Cells
It has been reported that one of the down-
stream pathways of BDNF/TrkB is PI3K-AKT 
pathway. To study whether this pathway regulates 
cell proliferation and migration in ovarian cancer, 
we silenced AKT1 by siRNA (Figure 4A), prolif-
eration assay showed no difference with scramble 
control group (Figure 4B). Invasion assays were 
performed, the result showed that knockdown of 
AKT1 showed no difference of migration ability 
of SKOV-3 cells (Figure 4C).
TrkB/PLCγ1 Signaling Pathway 
Is Necessary to Promote Proliferation 
and Migration of Ovarian Cancer Cells
It has been reported that one of the down-
stream pathways of BDNF/TrkB is PLCγ1 path-
way. To study whether this pathway regulates cell 
proliferation and migration in ovarian cancer, we 
silenced PLCγ1 by siRNA (Figure 5A), prolifera-
tion assay showed that, compared with scramble 
control group, BDNF couldn’t increase cell pro-
liferation without PLCγ1 (Figure 5B). Invasion 
assays showed that knockdown of PLCγ1 signifi-
cantly decreased cell migration ability of SKOV-3 
cells (Figure 5C).
Figure 2. BDNF promotes proliferation 
and migration and invasion of ovarian can-
cer cells. A, Cells were treated with BDNF 
(50 ng/ml) for 48 h, the proliferation of 
SKOV-3 cells increased significantly after 
5 days. Scratch assay showed higher motil-
ity of SKOV-3 cells after BDNF treatment 
(B), transwell migration (C) and invasion 
(D) assay suggested BDNF enhanced the 






BDNF promote proliferation and invasion of ovarian cancer cells
5097
TrkB/PLCγ1 Signaling Pathway 
Inhibits Cell Apoptosis to Promote 
Proliferation and Migration 
of Ovarian Cancer Cells
To demonstrate the mechanism of TrkB/PLCγ1 
signaling pathway, we detected the cell apoptosis in 
SKOV-3 cells. TUNEL assay was performed and the 
result showed that silencing of TrkB enhanced apop-
tosis of SKOV-3 cells. Further, silencing of PLCγ1 
by siRNA was sufficient to enhanced apoptosis of 
SKOV-3 cells (Figure 6A and 6B).
To summarize, our results demonstrated that 
BDNF-mediated progression of ovarian cancer is 
mediated by TrkB/PLCγ1 signaling pathway.
Discussion
Overexpression of growth factors and hor-
mones and abnormal expression or activation of 
their receptors may regulate the progression of 
many types of cancer including ovarian cancer. In 
this study, we investigated the role of the BDNF/
TrkB pathway in ovarian carcinogenesis. Immu-
nohistochemistry results showed increased BDNF 
and TrkB expression in ovarian cancers when 
compared with the normal ovary. This suggested 
that dysregulated TrkB expression was critical in 
ovarian carcinogenesis. More importantly, high 
TrkB expression level was associated with poor 
patient outcome and was an independent prognos-
tic factor11,12. 
BDNF could bind with TrkB and activate the 
downstream signaling pathway. It has been doc-
umented that an autocrine loop existed between 
TrkB and BDNF in malignant tumors such as 
neuroblastoma and myeloma 12,13. In the autocrine 
loop, high expression of BDNF induced expres-
sion of TrkB and vice versa. We found that both 
BDNF and TrkB were expressed in cancer cells 
Figure 3. BDNF upregulates expression 
and phosphorylation of TrkB and enhances 
cell proliferation and migration and inva-
sion. A, Treatment of BDNF recombinant 
protein promoted expression and activa-
tion of TrkB by Western blot. Silencing of 
TrkB by siTrkB (A) significantly abolished 
effects of BDNF on proliferation (B) and 










Figure 4. TrkB/PI3K signaling pathway 
is not necessary to promote proliferation 
and migration of ovarian cancer cells. A, 
Treatment of BDNF recombinant protein 
promoted phosphorylation of AKT1 by 
Western blot. Silencing of AKT1 by siAKT1 
(A) showed no effects of BDNF on prolifer-





Figure 5. TrkB/PLCγ1 signaling pathway 
is necessary to promote proliferation and 
migration of ovarian cancer cells. A, Treat-
ment of BDNF recombinant protein promot-
ed phosphorylation of PLCγ1 by Western 
blot. Silencing of PLCγ1 by siPLCγ1 (A) 
significantly abolished effects of BDNF on 
proliferation (B) and invasion (C) of SKOV-3 
cells. *p<0.05, ***p<0.001.
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and BDNF could activate TrkB on cancer cells 
and contribute to cancer progression. However, 
the mechanisms by which TrkB expression is in-
duced in ovarian tumors was still not clear. We 
then demonstrated that PLCγ1 other than AKT1 
is the necessary downstream effector of BDNF/
TrkB signaling pathway. When PLCγ1 was si-
lenced, BDNF induced cell proliferation and mi-
gration and invasion were hindered.
Several growth factors could activate PLCγ1 
and PLCγ1 is required for cell proliferation and 
motility and invasion in different cell types14,15. 
Strong evidence demonstrated that PLCγ1 is a 
critical enzyme in the development and main-
tenance of tumor metastasis. The role of PLCγ1 
in proliferation was first identified in the study 
of the growth factor signaling, such as through 
EGFR and platelet-derived growth factor recep-
tor (PDGFR) pathways. And a couple of studies 
have implicated PLCγ1 plays a critical role in the 
regulation of cancer cell invasion and metastasis 
via multiple mechanisms15. PLCγ1 is thought to 
regulate both cytoskeletal changes and migration 
associated with the metastatic process14-16. Here 
we showed PLCγ1 could inhibit apoptosis of can-
cer cells.
Conclusions
We showed here that the overexpression of 
TrkB predicts poor prognosis of ovarian cancer 
patients. Then, we demonstrated that BDNF/TrkB 
pathway promotes proliferation and invasion of 
ovarian cancer cell line SKOV-3. Furthermore, 
we reported PLCγ1 is the possible downstream 
effector of TrkB signaling pathways in promoting 
ovarian cancer proliferation and invasion by inhi-
bition of apoptosis which worth further research 
as potential therapeutic targets.
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